echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > ESMO Open: Among cancer patients undergoing anti-tumor therapy, the humoral immune response of BNT162b2 coronavirus 2019 messenger RNA vaccination decreased

    ESMO Open: Among cancer patients undergoing anti-tumor therapy, the humoral immune response of BNT162b2 coronavirus 2019 messenger RNA vaccination decreased

    • Last Update: 2021-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Cancer patients are at higher risk of severe COVID-19 (COVID-19)


    Cancer patients are at higher risk of severe COVID-19

    Patients and methods: In this interventional prospective multi-cohort study, patients with solid tumors receiving chemotherapy, immunotherapy, targeted or hormone therapy were given start-up and booster doses of BNT162b2 covid19 vaccine every 21 days, and received ritux Patients with hematological malignancies after ximab or allogeneic hematopoietic stem cell transplantation


    Results: Local and systemic adverse events (AEs) were mostly mild to moderate (only 1%-3% of patients experienced severe AEs)


    Figure 1 Local and systemic adverse events (AEs) were reported within 7 days after the initiation and enhancement of BNT162b2 vaccination; (A) local and (C) systemic adverse reactions pooled from all study cohorts, and based on the total study population It is expressed as a percentage (200 people were vaccinated and 197 people were boosted)


    Figure 2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-RBD antibody response after administration of BNT162b2 vaccine; virus neutralization test, neutralization titer is 50% (NT50), defined as SARS-CoV -2 (2019nCoV-Italia-INMI1 strain, number 008V-03893, 5th generation) the dilution (reciprocal titer) of the 50% neutralized sample in the infection well


    Figure 3 Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) produces neutralizing antibody response after vaccination with BNT162b2 vaccine; virus neutralization test, the neutralization titer is 50% neutralization titer (NT50), definition It is the sample dilution (reciprocal titer) of 50% neutralization in the SARS-CoV-2 (2019nCoV-Italia-INMI1 strain, number 008V-03893, 5th generation) infection well


    Conclusion: BNT162b2 vaccine is well tolerated in actively treated tumor patients


    The BNT162b2 vaccine is well tolerated in actively treated cancer patients


    Peeters M, Verbruggen L, Teuwen L,et al, Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment .


    Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.